View Older Stories

Jun 25, 2026 08:05AM Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer

Jun 2, 2026 08:05AM Candel publishes phase 3 prostate cancer trial data in Lancet Oncology

Jun 2, 2026 08:05AM Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Loca

Jun 1, 2026 04:05PM Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 15, 2026 04:05PM Candel Therapeutics reports extended clinical benefits in phase 3 prostate cancer trial

May 15, 2026 04:05PM Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonge

May 14, 2026 08:05AM Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

May 13, 2026 08:05AM Candel Therapeutics to Present at Upcoming Investor Conferences

May 4, 2026 08:05AM Candel Therapeutics schedules call on prostate cancer trial data

May 4, 2026 08:05AM Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Asso

May 1, 2026 04:05PM Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 29, 2026 08:05AM Candel Therapeutics partners with EVERSANA for drug commercialization

Apr 29, 2026 08:05AM Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer

Apr 2, 2026 04:05PM Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 17, 2026 08:05AM Candel reports extended survival in lung cancer trial

Mar 17, 2026 08:05AM Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoin

Mar 12, 2026 08:05AM Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Mar 9, 2026 08:05AM Candel Therapeutics to present prostate cancer trial data at AUA meeting

Mar 9, 2026 08:05AM Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annu

Mar 2, 2026 04:05PM Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 24, 2026 08:05AM Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston

Feb 19, 2026 09:40PM Candel Therapeutics prices $100 million public offering at $5.45 per share

Feb 19, 2026 09:40PM Candel Therapeutics Announces Pricing of Public Offering

Feb 19, 2026 04:05PM Candel Therapeutics launches $100 million public offering

Feb 19, 2026 04:05PM Candel Therapeutics Announces Proposed $100 Million Public Offering

Feb 19, 2026 04:02PM Candel Therapeutics secures $100M royalty funding deal with RTW

Feb 19, 2026 04:01PM Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

Feb 11, 2026 08:05AM Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit

Feb 2, 2026 04:05PM Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 17, 2025 04:05PM Candel Therapeutics to Host Virtual R&D Event on December 5, 2025

Nov 17, 2025 04:05PM Candel Therapeutics to Host Virtual R&D Event on December 5, 2025

Nov 13, 2025 08:25AM Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Nov 4, 2025 09:00AM Candel Therapeutics to present phase 3 prostate cancer trial results at SITC

Nov 4, 2025 09:00AM Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapi

Nov 3, 2025 08:05AM Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London

Oct 16, 2025 08:05AM Candel Therapeutics adds systems immunology expert to advisory board

Oct 16, 2025 08:05AM Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

Oct 14, 2025 08:12AM Candel Therapeutics secures $130 million term loan facility with Trinity Capital

Oct 14, 2025 08:10AM Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.

Oct 14, 2025 08:07AM Candel Therapeutics reports interim data on CAN-3110 for glioblastoma

Oct 14, 2025 08:05AM Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine

Oct 3, 2025 09:05AM Candel Therapeutics to Present at the SITC 2025 Annual Meeting

Sep 29, 2025 08:05AM Candel presents prostate cancer trial data showing therapy works across radiation types

Sep 29, 2025 08:05AM Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Sep 17, 2025 08:05AM Candel Therapeutics to present phase 3 prostate cancer data at ASTRO

Sep 17, 2025 08:05AM Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Sep 2, 2025 08:05AM Candel Therapeutics adds CAR-T pioneer Carl June to advisory board

Sep 2, 2025 08:05AM Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board

Aug 28, 2025 08:05AM Candel Therapeutics to Participate in Upcoming Investor Conferences in September

Aug 14, 2025 08:05AM Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

View Older Stories